Canlyniadau Chwilio - Ignacio Garrido‐Laguna

Mireinio'r Canlyniadau
  1. 1
    TIGIT: a novel immunotherapy target moving from bench to bedside

    TIGIT: a novel immunotherapy target moving from bench to bedside gan Benjamin L. Solomon, Ignacio Garrido‐Laguna

    Cyhoeddwyd 2018
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Novel Therapeutic Targets in Non-small Cell Lung Cancer

    Novel Therapeutic Targets in Non-small Cell Lung Cancer gan Filip Janků, Ignacio Garrido‐Laguna, Luboš Petruželka, David J. Stewart, Razelle Kurzrock

    Cyhoeddwyd 2011
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Combination immunotherapy and radiation therapy strategies for pancreatic cancer—targeting multiple steps in the cancer immunity cycle

    Combination immunotherapy and radiation therapy strategies for pancreatic cancer—targeting multiple steps in the cancer immunity cycle gan Snehal Gajiwala, Anna Torgeson, Ignacio Garrido‐Laguna, Conan G. Kinsey, Shane Lloyd

    Cyhoeddwyd 2018
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Response of Histiocytoses to Imatinib Mesylate: Fire to Ashes

    Response of Histiocytoses to Imatinib Mesylate: Fire to Ashes gan Filip Janků, Hesham M. Amin, Dan Yang, Ignacio Garrido‐Laguna, Jonathan C. Trent, Razelle Kurzrock

    Cyhoeddwyd 2010
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer

    Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer gan Anna Torgeson, Shane Lloyd, Dustin Boothe, Randa Tao, Jonathan Whisenant, Ignacio Garrido‐Laguna, George M. Cannon

    Cyhoeddwyd 2017
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Entrectinib in <i>TRK</i> and <i>ROS1</i> Fusion-Positive Metastatic Pancreatic Cancer

    Entrectinib in <i>TRK</i> and <i>ROS1</i> Fusion-Positive Metastatic Pancreatic Cancer gan Michael J. Pishvaian, Ignacio Garrido‐Laguna, Stephen V. Liu, Pratik S. Multani, Edna Chow‐Maneval, Christian Rolfo

    Cyhoeddwyd 2018
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    <i>KRAS</i> Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma

    <i>KRAS</i> Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma gan Carter Norton, Matthew Shaw, Zachary Rubnitz, Jarrod Smith, Heloisa P. Soares, Christopher Nevala-Plagemann, Ignacio Garrido‐Laguna, Vaia Florou

    Cyhoeddwyd 2025
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center

    Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center gan Ignacio Garrido‐Laguna, Filip Janků, Christos Vaklavas, Gerald S. Falchook, Siqing Fu, David S. Hong, Aung Naing, Apostolia M. Tsimberidou, Sijin Wen, Razelle Kurzrock

    Cyhoeddwyd 2011
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers

    PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers gan Filip Janků, J. Jack Lee, Apostolia M. Tsimberidou, David S. Hong, Aung Naing, Gerald S. Falchook, Siqing Fu, Rajyalakshmi Luthra, Ignacio Garrido‐Laguna, Razelle Kurzrock

    Cyhoeddwyd 2011
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors

    KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors gan Ignacio Garrido‐Laguna, David S. Hong, Filip Janků, Ly M. Nguyen, Gerald S. Falchook, Siqing Fu, J. J. Wheler, Rajyalakshmi Luthra, Aung Naing, Xuemei Wang, Razelle Kurzrock

    Cyhoeddwyd 2012
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer

    A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer gan Manuel Hidalgo, Elizabeth Bruckheimer, N.V. Rajeshkumar, Ignacio Garrido‐Laguna, Elizabeth De Oliveira, Belén Rubio‐Viqueira, Steven J. Strawn, Michael J. Wick, James Martell, David Sidransky

    Cyhoeddwyd 2011
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors

    A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors gan Niharika B. Mettu, Susanna V. Ulahannan, Johanna C. Bendell, Ignacio Garrido‐Laguna, John H. Strickler, Kathleen N. Moore, Robert Stagg, Ann M. Kapoun, Leonardo Faoro, Sunil Sharma

    Cyhoeddwyd 2021
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    <i>PIK3CA</i> Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

    <i>PIK3CA</i> Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors gan Filip Janků, Apostolia M. Tsimberidou, Ignacio Garrido‐Laguna, Xuemei Wang, Rajyalakshmi Luthra, David S. Hong, Aung Naing, Gerald S. Falchook, John W. Moroney, Sarina A. Piha‐Paul, Jennifer J. Wheler, Stacy Moulder, Siqing Fu, Razelle Kurzrock

    Cyhoeddwyd 2011
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  14. 14
    PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring <i>PIK3CA</i> Mutations

    PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring <i>PIK3CA</i> Mutations gan Filip Janků, Jennifer J. Wheler, Shannon N. Westin, Stacy Moulder, Aung Naing, Apostolia M. Tsimberidou, Siqing Fu, Gerald S. Falchook, David S. Hong, Ignacio Garrido‐Laguna, Rajyalakshmi Luthra, J. Jack Lee, Karen H. Lu, Razelle Kurzrock

    Cyhoeddwyd 2012
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  15. 15
    Personalizing Cancer Treatment in the Age of Global Genomic Analyses: <i>PALB2</i> Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer

    Personalizing Cancer Treatment in the Age of Global Genomic Analyses: <i>PALB2</i> Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer gan Maria Cristina Villarroel, N.V. Rajeshkumar, Ignacio Garrido‐Laguna, Ana De Jesus‐Acosta, Siân Jones, Anirban Maitra, Ralph H. Hruban, James R. Eshleman, Alison P. Klein, Daniel A. Laheru, Ross C. Donehower, Manuel Hidalgo

    Cyhoeddwyd 2010
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  16. 16
    PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes

    PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes gan Filip Janků, Jennifer J. Wheler, Aung Naing, Vanda M. Stepanek, Gerald S. Falchook, Siqing Fu, Ignacio Garrido‐Laguna, Apostolia M. Tsimberidou, Sarina A. Piha‐Paul, Stacy Moulder, J. Jack Lee, Rajyalakshmi Luthra, David S. Hong, Razelle Kurzrock

    Cyhoeddwyd 2012
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  17. 17
    First‐in‐human, phase I study of PF‐06647263, an anti‐EFNA4 calicheamicin antibody–drug conjugate, in patients with advanced solid tumors

    First‐in‐human, phase I study of PF‐06647263, an anti‐EFNA4 calicheamicin antibody–drug conjugate, in patients with advanced solid tumors gan Ignacio Garrido‐Laguna, Ian E. Krop, Howard A. Burris, Erika Hamilton, Fadi Braiteh, Amy Weise, Maysa Abu‐Khalaf, Theresa L. Werner, Steven Pirie‐Shepherd, Christopher J. Zopf, Mani Lakshminarayanan, Jaymes Holland, Raffaele Baffa, David S. Hong

    Cyhoeddwyd 2019
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  18. 18
    Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors

    Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors gan Anthony B. El-Khoueiry, James S. Clarke, Tobias Neff, T. Crossman, Nirav Ratia, Chetan Rathi, Paul Noto, Aarti Tarkar, Ignacio Garrido‐Laguna, Emiliano Calvo, Jordi Rodón, Ben Tran, Peter J. O’Dwyer, Adam Cuker, Albiruni R. Abdul Razak

    Cyhoeddwyd 2023
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  19. 19
    Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC

    Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC gan Vaia Florou, Andrew Elliott, Matthew H. Bailey, David Stone, Kajsa E. Affolter, Heloisa P. Soares, Christopher Nevala-Plagemann, Courtney L. Scaife, Phillip Walker, W. Michael Korn, Emil Lou, Rachna T. Shroff, Peter J. Hosein, Ignacio Garrido‐Laguna

    Cyhoeddwyd 2023
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  20. 20
    652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)

    652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (... gan Kathryn C. Arbour, Salman Rafi Punekar, Ignacio Garrido‐Laguna, David S. Hong, Brian M. Wolpin, Meredith S. Pelster, M. Barve, Alexander Starodub, D. Sommerhalder, Sam S. Chang, Y. Zhang, Zeena Salman, X. Wang, Corinne E. Gustafson, Alexander I. Spira

    Cyhoeddwyd 2023
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: